USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: CELLECTA, INC.
City: MOUNTAIN VIEW
State: CA
Zip+4: 94043-4040
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,848,119.00 10
SBIR Phase II $7,105,086.00 4

Award List:

High Throughput Screening of Peptide Pharmaceuticals

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alex Chenchik
Award Amount: $252,345.00
Abstract:
DESCRIPTION (provided by applicant): Despite the recent completion of the human genome project, an ostensibly more difficult post-genomic challenge will be the functional annotation of all human genes and integration of this information into a rational dr ug discovery process. Unfortunately, this… More

Functionally Validated Lentiviral siRNA Libraries

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alex Chenchik
Award Amount: $289,398.00
Abstract:
DESCRIPTION (provided by applicant): Despite the recent completion of the human genome project, an ostensibly more difficult post-genomic challenge will be the functional annotation of all human genes and integration of this information into an operational cell-based model. Unfortunately, this is… More

Algorithm and genome-wide database of functional siRNAs

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: Alex Chenchik
Award Amount: $2,379,611.00
Abstract:
DESCRIPTION (provided by applicant): Despite the recent completion of the human genome project, an ostensibly more difficult post-genomic challenge will be the functional annotation of all human genes and integration of this information into an operationa l cell-based model. Unfortunately, this is… More

Array-assisted Insertional Mutagenesis Platform for Forward Genetics of Cancer

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alex Chenchik
Award Amount: $187,669.00
Abstract:
DESCRIPTION (provided by applicant): Despite the recent completion of the human genome project, an ostensibly more difficult post-genomic challenge will be the functional annotation of all human genes and integration of this information into an operational cell-based model. Unfortunately, this is… More

Viability Pathway Models in Prostate Cancer Cells

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alex Chenchik
Award Amount: $298,073.00
Abstract:
DESCRIPTION (provided by applicant): Despite the rapid advances in elucidating the molecular basis of cancer, an ostensibly more difficult post-genomic challenge will be the functional annotation of signaling pathways and integration of this information in to an operational cell-based model.… More

Identification of Hematopoietic Stem and Progenitor Cell Viability Genes

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kyle R. Bonneau
Award Amount: $249,465.00
Abstract:
DESCRIPTION (provided by applicant): More than 15,000 allogeneic and 30,000 autologous hematopoietic stem cell transplantations (HSCT) are performed annually worldwide (1). Approximately 40% of patients that undergo allogeneic HSCT die from transplantation -related complications, in part due to… More

Drug Targets of Heat Shock Response

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Andrey K. Komarov
Award Amount: $237,368.00
Abstract:
DESCRIPTION (provided by applicant): The heat shock response (HSR) induced by cell stress is a common protection mechanism elicited in a wide range of tumors. This response is closely associated with a poor prognosis and resistance to therapy. Phase I of t his proposed research aims to identify drug… More

Inhibitors of Heat Shock Response

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Andrey K. Komarov
Award Amount: $234,168.00
Abstract:
DESCRIPTION (provided by applicant): The recent development of anti-cancer pharmaceuticals has resulted in the isolation of several effective blockers of constitutive heat shock response (HSR), such as the HSP90 inhibitor Geldanamycin (DMAG) and the protea some inhibitor Velcade (Bortezomib), which… More

Not Available

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alexandr Chenchik – (650) 938-3914
Award Amount: $199,681.00
Abstract:
Despite rapid advances in elucidating the molecular basis of human diseases, an ostensibly more difficult post-genomic challenge is the functional annotation of disease-specific signaling pathways and the application of this information for the development of novel drugs. RNA interference (RNAi) now… More

Functionally Validated Lentiviral siRNA libraries

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Alex Chenchik
Award Amount: $1,860,304.00
Abstract:
DESCRIPTION (provided by applicant): Despite rapid advances in elucidating the molecular basis of human diseases, an ostensibly more difficult post-genomic challenge is the functional annotation of disease-specific signaling pathways and integration of thi s information into the development of novel… More

Isolation of Peptide Radioprotectors

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Andrey Komarov
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): Systemic exposure to ionizing radiation (IR) results in cell damage in radiosensitive tissues. It is therefore highly desirable to develop efficient radioprotective agents for use in cancer radiotherapy, and biodefense. We have discovered a new class of… More

Exploiting synthetic lethality of hematopoietic lineage cells to develop novel ta

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Kyle R. Bonneau – 650-938-3915
Award Amount: $1,865,575.00
Abstract:
DESCRIPTION (provided by applicant): Targeted therapies have the ability to specifically interact with and block proliferation of cancer cells by interfering with targeted gene products required for the malignant phenotype. Unlike conventional cancer chemotherapies, targeted therapies do not harm… More

IGF::OT::IGF SBIR PHASE II TOPIC 290 RNAI SYNTHETIC LETHAL SCREEN IN CANCER CELL MODELS.

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Karim Hyder – 650-938-3914
Award Amount: $999,596.00
Abstract:
The DNA Damage and Repair (DDR) signaling modules are among the most commonly deregulated genes in human tumors. Deficiencies in DDR pathways are believed to influence tumorigenic processes by promoting a mutator phenotype, which contributes to the acquisition of genetic lesions and fuels… More

TOPIC 316 PHASE I: GENETIC ANALYSIS OF CTCS AT THE SINGLE CELL LEVEL; HHSN261201

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alexander Chenchik – 650-938-3914
Award Amount: $299,952.00
Abstract:
Not Available